iXLife

iXLife Capital is a venture capital fund that invests in early-stage biotechnology companies focused on innovative therapies and drug discovery. The firm manages a €50 million venture capital fund, supporting biotech ventures developing treatments for diseases such as age-related macular degeneration and hepatitis, with a particular interest in immunotherapy and cell death inhibition therapies. Its portfolio includes companies like SeaBeLife, Theravectys, and VAXON-Biotech, with Jean-Pierre Kinet serving as Managing Partner and chairman. In 2025, iXLife Capital led a €2 million funding round for SeaBeLife to advance drug candidates, targeting a first clinical trial in 2026. The fund has also backed Theravectys, an immunotherapy biotech founded in 2005, which is reportedly planning a Hong Kong IPO by January 2026. Its business model centers on manages a €50M venture capital fund to invest in biotech startups.